

# ForPatients

by Roche

[Early Breast Cancer](#) [Breast Cancer](#) [Er-Positive Breast Cancer](#) [HER-2 Negative Breast Cancer](#)

## A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (IidERA Breast Cancer)

**Trial Status**

Active, not recruiting

**Trial Runs In**

54 Countries

**Trial Identifier**

NCT04961996

2021-000129-28,2023-507172-44-00

GO42784

---

The source of the below information is the publicly available website [ClinicalTrials.gov](#). It has been summarised and edited into simpler language.

### ***Trial Summary:***

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of endocrine therapy in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

**Hoffmann-La Roche**

Sponsor

**Phase 3**

Phase

---

**NCT04961996 2021-000129-28,2023-507172-44-00 GO42784**

Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**

All

**Age**

>=18 Years

**Healthy Volunteers**

No

---